Saturday, November 6, 2021
- 8:30AM-10:30AM
-
Abstract Number: 0393
Severity and Impact of Gastrointestinal Symptoms in Patients with SSc-ILD Treated with Nintedanib: Data from SENSCIS-ON
Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)- 8:30AM-10:30AM
-
Abstract Number: 0299
Sex Hormones and Risk of Sjögren’s Syndrome: Hypothesis Generating Findings Implicating Androgen and Estrogen Ratios
Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)- 8:30AM-10:30AM
-
Abstract Number: 0165
Shear-Wave Elastography Evaluation of Major Salivary Glands and Correlation with B-mode Findings in Patients with Primary Sjögren’s Syndrome
Imaging of Rheumatic Diseases Poster (0149–0182)- 8:30AM-10:30AM
-
Abstract Number: 0380
Sick Leave and Its Predictors in Early Axial Spondyloarthritis: The Role of Clinical and Socioeconomic Factors. Five-year Data from the DESIR Cohort
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)- 8:30AM-10:30AM
-
Abstract Number: 0382
Six-year Results from the Esperanza Cohort: Evaluation of Clinical Features, Disease Activity Measures and Treatment Aspects in Axial and Peripheral Early Spondyloarthritis
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)- 8:30AM-10:30AM
-
Abstract Number: 0315
Sjögren’s Syndrome Symptom Diary (SSSD) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) as Assessments of Symptoms in Sjögren’s Syndrome: A Qualitative Exploration of Content Validity and Meaningful Change
Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)- 8:30AM-10:30AM
-
Abstract Number: 0308
Sleep Disorders and Serum Brain-derived Neurotrophic Factor Levels in Patients with Primary Sjögren’s Syndrome
Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)- 8:30AM-10:30AM
-
Abstract Number: 0353
Soluble Urine ALCAM Reflects Renal Disease Activity in Lupus Nephritis
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)- 8:30AM-10:30AM
-
Abstract Number: 0016
Structural and Functional Neurobiological Alterations of Salience and Sensorimotor Networks in Juvenile Idiopathic Arthritis
RA – Etiology & Pathogenesis Poster (0011–0045)- 8:30AM-10:30AM
-
Abstract Number: 0159
Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time?
Imaging of Rheumatic Diseases Poster (0149–0182)- 8:30AM-10:30AM
-
Abstract Number: 0090
Subcutaneous Sarilumab in Hospitalized Patients with Moderate-severe COVID-19 Infection Compared to the Standard Care: An Open-label Randomized Clinical Trial
Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)- 8:30AM-10:30AM
-
Abstract Number: 0197
Successful Treatment of Severe COVID-19 Pneumonia with Simultaneous Tocilizumab and Anakinra – A Case Series
Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)- 8:30AM-10:30AM
-
Abstract Number: 0292
Suppressed Paraoxonase-1 Activity and Elevated Oxylipins Associate with the Presence of Small Airways Disease in Patients with Rheumatoid Arthritis
RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)- 8:30AM-10:30AM
-
Abstract Number: 0053
Susceptibility Factors for Psoriatic Arthritis Single-cell RNA-Sequencing of Patients with Psoriatic Disease